Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36673829

about

Transarterial radioembolization for hepatocellular carcinoma: a review The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review Current status of transarterial radioembolization Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.Radioembolization for the treatment of hepatocellular carcinoma Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma.Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.Hepatocellular carcinoma: From diagnosis to treatment.Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients.Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.Hepatocellular carcinoma and cholangiocarcinoma: an update.Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management.How does selective internal radiation therapy compare with and/or complement other liver-directed therapies.Current management of hepatocellular carcinoma: an Eastern perspective.(90)Y-glass microspheres for hepatic neoplasia.Current role of selective internal radiation with yttrium-90 in liver tumors.Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis.Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma.Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review.Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma.Application of embolization microspheres in interventional therapy of malignant non-hypervascular tumor of liver.Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.

P2860

Q26738273-5B9C657D-803E-4866-98CC-19D8419F336B Q26741882-622E60D8-C430-4D9B-873F-B9C5C780DD84 Q26743603-A748CF31-4211-493A-98D0-263BCCF89F89 Q26744307-F1E50355-5EF8-4B38-8840-56188F4725EB Q26753089-85A7CBB2-5C21-483D-86D4-1E8FD14012BA Q26799469-170B9874-249C-40E7-AD2B-8B144ACF5939 Q28077829-7791EBF3-4401-44EF-9C69-AF8F901630EB Q28081783-69FBF56D-CFD5-43B5-88F5-C72D11BD620B Q30248206-047213AE-E780-4B99-976E-FC52C5710253 Q33872976-31F1113E-53CA-4727-B031-FC1BC612F37D Q34077181-64B8C12C-456B-42B0-8281-BA516CB9070C Q34702094-7654FCDF-7422-4A75-949D-CAA9EBAB5109 Q35037545-92FAEC39-998C-42D9-A26D-15381F5E1AAF Q35164855-28BC7028-4CAD-4156-9F63-C7FF859D3072 Q35506937-67FC910B-A5FD-4AE1-A472-EBE7895D8482 Q35631304-7C8053C0-95BF-4404-AEBF-AA6D160A0392 Q35668716-7E5C78B6-6170-4052-B838-CB44A448E800 Q36278698-C27CAE51-DB57-4156-8B50-F2A0BD73E0B0 Q36886453-52639AB2-0032-4CDD-B220-B6A505D0900E Q37474833-7301B878-0D64-44B7-BF53-EE4894910CA2 Q37687824-EBE67086-9541-4C68-8BEA-DBA8F2CC6DFF Q37706378-B4923938-B424-4EF6-ABAE-0F7BB3CD05BC Q37716505-AD2462C2-F88E-4473-89EC-3E477CC6F987 Q38162894-20667D1F-1CDE-4390-9123-0F5922483BA9 Q38163597-33D2A577-CAAE-43D6-B0A3-9FB34161EFB3 Q38283651-3F9CADE6-20CC-430F-8631-A4C0FA293270 Q38283692-A46AB41B-EB0D-4E8D-A412-3CC85066F725 Q38410816-5F1D3B5F-8C56-4133-BC09-7B3AE62D0B02 Q38465831-909356EE-D6E0-4315-8BE3-304BF1F0D63B Q38786064-DCF4C0E7-45E0-4045-A84D-6D8E0DD7F1DA Q38792625-5C912367-ED51-41E0-A10D-1585DDD82C90 Q38820543-A7519129-044A-495C-AC13-F9B021D1A5BF Q38883028-7EE082E4-4722-4257-9BF4-B4FE85B8B80D Q38979742-F2F98743-83EC-495D-8AED-5B39E942458E Q39240641-9B6E50B9-C838-46EC-816E-F9DFE665BB50 Q40389227-2AA9F009-33CE-43A5-9868-36CF1D5EE21D Q40705749-BD93D393-D815-4A32-8DD8-A3E7F5C8F623 Q41547755-79B0B8D3-FB3E-45F8-B451-E4B6EDEA31D9 Q43961233-1FE596E6-3468-4295-956F-3C5851375257 Q47724444-54541FC8-68FF-4AAE-AC54-D4030A490608

P2860

Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36673829

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy and safety of transar ...... with hepatocellular carcinoma.

@ast

Efficacy and safety of transar ...... with hepatocellular carcinoma.

@en

type

label

Efficacy and safety of transar ...... with hepatocellular carcinoma.

@ast

Efficacy and safety of transar ...... with hepatocellular carcinoma.

@en

prefLabel

Efficacy and safety of transar ...... with hepatocellular carcinoma.

@ast

Efficacy and safety of transar ...... with hepatocellular carcinoma.

@en

P1433

Q36673829-D374E373-4477-4569-80FB-1C2B83A0DE03

P1476

Q36673829-D3C318E5-BF74-413D-9F59-35305909ED24

P2093

Q36673829-0F185AF8-6F44-4FF9-B2EF-E9B7CF46EB70

Q36673829-156983FF-22AC-4DA8-AB9F-FDEFB0EAE3AC

Q36673829-40FCE9B7-4E64-42F2-AEA4-E04137BDDED2

Q36673829-49C30F88-156A-4E4D-BB6E-C0FD8D080FCE

Q36673829-66F2DA65-C194-4889-BAEF-6E9A90C3EC74

Q36673829-68D118F9-31C1-46D4-9211-E63C149B9B43

Q36673829-86D0A366-5CEE-406B-9350-75F6DED1841A

Q36673829-893F9385-5D98-43DC-BC83-498F993A12E2

Q36673829-8C81C644-4B79-4387-9FE0-AF2A4995EA1C

Q36673829-8D2D6D38-9792-423A-BDAC-FBE6218DA60A

P2860

Q36673829-0CDB428C-F730-4F1A-8296-9045F24074D0

Q36673829-190BBC37-9BA0-4BBD-BD90-56B22D90C31C

Q36673829-1A14372C-71C3-439C-93AF-4F1068BBDFD5

Q36673829-278D7CAD-B304-45CF-845C-2EB1608CE2C7

Q36673829-38F8A6E7-C364-4D77-B5D1-694C56721F57

Q36673829-39037FCE-EC68-4672-AB13-BE9F070A0AEB

Q36673829-3C050069-6A06-4C09-AE1C-78CA8CB0B36E

Q36673829-403879DE-90B8-423B-BBB3-264B5A871008

Q36673829-54FBFB84-F8A7-44F8-B2C3-52F6495B3431

Q36673829-7370568A-A70B-4D0C-8871-679F5FCB341B

P2888

Q36673829-F92A1A15-02BA-4CED-AB2E-20DEDC8CB06F

P304

Q36673829-80EC97B3-D380-4C68-961A-D5DF4F77C438

P31

Q36673829-54F7C033-E888-44AD-901C-25904507E368

P356

Q36673829-822D3E3B-8605-46C8-8643-08417250C958

P433

Q36673829-00B49ACF-66A6-4B5A-8B47-2CBD77257BE5

P478

Q36673829-55518193-CEC3-405B-8BEB-73928AB9A170

P50

Q36673829-7BD12177-CBF2-4BD2-86F2-2EA45116A733

Q36673829-A5D3678E-B203-439C-A30A-87E530910059

P577

Q36673829-FD6E2212-6A5F-4781-BF2E-36506D9CB415

P698

Q36673829-B6DB1D82-0469-4B07-B23B-F7A517D7ACC3

P932

Q36673829-D3064ABC-D3A5-4008-BBDC-27C81F474BAC

P356

S00270-012-0481-2

P1433

CardioVascular and Interventional Radiology

P1476

Efficacy and safety of transar ...... with hepatocellular carcinoma

@en

P2093

Chad J Fleming

http://www.w3.org/2001/XMLSchema#string

Denise M Harnois

http://www.w3.org/2001/XMLSchema#string

Denise N Gansen

http://www.w3.org/2001/XMLSchema#string

Gregory A Wiseman

http://www.w3.org/2001/XMLSchema#string

James C Andrews

http://www.w3.org/2001/XMLSchema#string

Ju Dong Yang

http://www.w3.org/2001/XMLSchema#string

K V Narayanan Menon

http://www.w3.org/2001/XMLSchema#string

Konstantinos N Lazaridis

http://www.w3.org/2001/XMLSchema#string

Laura E Moreno-Luna

http://www.w3.org/2001/XMLSchema#string

Nicholas F Larusso

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Management of hepatocellular carcinoma

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.

Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.

P2888

s00270-012-0481-2

P304

714-723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00270-012-0481-2

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Lewis R. Roberts

Gregory J Gores

P577

2012-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23093355

http://www.w3.org/2001/XMLSchema#string

P932

3594060

http://www.w3.org/2001/XMLSchema#string